Catalyst jumps after Q4 revenue beat

Catalyst Pharmaceuticals

29/02/2024 11:02

** Shares of drugmaker Catalyst Pharmaceuticals  CPRX.O 
rise ~13% to $16.48 premarket
    ** Co's Q4 revenue of $110.6 mln beats analysts' average
expectation of $105.9 mln - LSEG data
    ** Co says neuromuscular disorder drug Firdapse's Q4 net
product revenue rose 15% to $69.8 mln
    ** CPRX forecasts annual revenue between $455 mln and $475
mln, the midpoint of which is above analysts' average estimate
of $463.2 mln
    ** Up to last close, stock down 4.6% in the last 12 months

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))